Treatment of primary osteoporosis in men

References

• NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and TherapyOsteoporosis prevention, diagnosis, and therapyJAMA2001285678579511176917
   PubMed Web of Science ®Google Scholar
• KhoslaSAminSOrwollEOsteoporosis in menEndocr Rev200829444146418451258
   PubMed Web of Science ®Google Scholar
• DrakeMTKhoslaSMale osteoporosisEndocrinol Metab Clin North Am201241362964122877433
   PubMed Web of Science ®Google Scholar
• GiustiAPapapoulosSETreatment of male osteoporosis with bisphosphonatesOrwollEBilezikianJVanderschuerenDOsteoporosis in Men: The Effects of Gender on Skeletal HealthWaltham, MAAcademic Press2009667679
   Google Scholar
• KaufmanJMReginsterJYBoonenSTreatment of osteoporosis in menBone201353113414423201268
   PubMed Web of Science ®Google Scholar
• KanisJAOdenAJohnellOThe use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and womenOsteoporos Int20071881033104617323110
   PubMed Web of Science ®Google Scholar
• KanisJAOdenAJohanssonHBorgströmFStrömOMcCloskeyEFRAX and its applications to clinical practiceBone200944573474319195497
   PubMed Web of Science ®Google Scholar
• AdamiSRomagnoliECarnevaleVItalian Society for Osteoporosis, Mineral Metabolism and Bone Diseases (SIOMMMS)Guidelines on prevention and treatment of vitamin D deficiency. Italian Society for Osteoporosis, Mineral Metabolism and Bone Diseases (SIOMMMS)Reumatismo2011633129147 Italian22257914
   PubMedGoogle Scholar
• OrwollESOsteoporosis in menRosenCPrimer on the Metabolic Bone Diseases and Disorders of Mineral MetabolismWashington DCAmerican Society for Bone and Mineral Research2013508513
   Google Scholar
• BoonenSReginsterJYKaufmanJMFracture risk and zoledronic acid therapy in men with osteoporosisN Engl J Med2012367181714172323113482
   PubMed Web of Science ®Google Scholar
• LylesKWColón-EmericCSMagazinerJSHORIZON Recurrent Fracture TrialZoledronic acid and clinical fractures and mortality after hip fractureN Engl J Med2007357181799180917878149
   PubMed Web of Science ®Google Scholar
• BrumsenCPapapoulosSELipsPDaily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extensionJ Bone Miner Res20021761057106412054161
   PubMed Web of Science ®Google Scholar
• RingeJDFarahmandPFaberHDorstASustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year studyRheumatol Int200929331131518762944
   PubMed Web of Science ®Google Scholar
• OrwollESMillerPDAdachiJDEfficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled studyJ Bone Miner Res201025102239225020499357
   PubMed Web of Science ®Google Scholar
• RingeJDDorstAFarahmandPEfficacy of strontium ranelate on bone mineral density in men with osteoporosisArzneimittelforschung201060526727220533764
   PubMed Web of Science ®Google Scholar
• FinkelsteinJSHayesAHunzelmanJLWylandJJLeeHNeerRMThe effects of parathyroid hormone, alendronate, or both in men with osteoporosisN Engl J Med2003349131216122614500805
   PubMed Web of Science ®Google Scholar
• OrwollESScheeleWHPaulSThe effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosisJ Bone Miner Res200318191712510800
   PubMed Web of Science ®Google Scholar
• OrwollEEttingerMWeissSAlendronate for the treatment of osteoporosis in menN Engl J Med2000343960461010979796
   PubMed Web of Science ®Google Scholar
• RingeJDDorstAFaberHIbachKAlendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm studyRheumatol Int200424211011313680141
   PubMed Web of Science ®Google Scholar
• SawkaAMPapaioannouAAdachiJDGafniAHanleyDAThabaneLDoes alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in womenBMC Musculoskelet Disord200563916008835
   PubMed Web of Science ®Google Scholar
• BoonenSOrwollESWenderothDStonerKJEusebioRDelmasPDOnce-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter studyJ Bone Miner Res200924471972519049326
   PubMed Web of Science ®Google Scholar
• BoonenSOrwollEMagazinerJHORIZON Recurrent Fracture TrialOnce-yearly zoledronic acid in older men compared with women with recent hip fractureJ Am Geriatr Soc201159112084209022091563
   PubMed Web of Science ®Google Scholar
• RuzaIMirfakhraeeSOrwollEGruntmanisUClinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: evidence and opinionsTher Adv Musculoskelet Dis20135418219823904863
   PubMedGoogle Scholar
• OrwollESBinkleyNCLewieckiEMGruntmanisUFriesMADasicGEfficacy and safety of monthly ibandronate in men with low bone densityBone201046497097620060082
   PubMed Web of Science ®Google Scholar
• SimIeWEbelingPRTreatment of osteoporosis in men with bisphosphonates: rationale and latest evidenceTher Adv Musculoskelet Dis20135525926724101947
   PubMedGoogle Scholar
• BlackDMCummingsSRKarpfDBRandomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research GroupLancet19963489041153515418950879
   PubMed Web of Science ®Google Scholar
• CummingsSRBlackDMThompsonDEEffect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention TrialJAMA199828024207720829875874
   PubMed Web of Science ®Google Scholar
• LibermanUAWeissSRBröllJEffect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study GroupN Engl J Med199533322143714437477143
   PubMed Web of Science ®Google Scholar
• PolsHAFelsenbergDHanleyDAMultinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study GroupOsteoporos Int19999546146810550467
   PubMed Web of Science ®Google Scholar
• HarrisSTWattsNBGenantHKEffects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study GroupJAMA1999282141344135210527181
   PubMed Web of Science ®Google Scholar
• McClungMRGeusensPMillerPDHip Intervention Program Study GroupEffect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study GroupN Engl J Med2001344533334011172164
   PubMed Web of Science ®Google Scholar
• ReginsterJYMinneHWSorensenOHRandomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study GroupOsteoporos Int2000111839110663363
   PubMed Web of Science ®Google Scholar
• ChesnutIII CHSkagAChristiansenCOral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE)Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosisJ Bone Miner Res20041981241124915231010
   PubMed Web of Science ®Google Scholar
• BlackDMDelmasPDEastellRHORIZON Pivotal Fracture TrialOnce-yearly zoledronic acid for treatment of postmenopausal osteoporosisN Engl J Med2007356181809182217476007
   PubMed Web of Science ®Google Scholar
• CusanoNECostaAGSilvaBCBilezikianJPTherapy of osteoporosis in men with teriparatideJ Osteoporos2011201146367522132345
   PubMedGoogle Scholar
• KaufmanJMOrwollEGoemaereSTeriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapyOsteoporos Int200516551051615322742
   PubMed Web of Science ®Google Scholar
• LederBZNeerRMWylandJJLeeHWBurnett-BowieSMFinkelsteinJSEffects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosisJ Clin Endocrinol Metab20099482915292119435827
   PubMed Web of Science ®Google Scholar
• NeerRMArnaudCDZanchettaJREffect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosisN Engl J Med2001344191434144111346808
   PubMed Web of Science ®Google Scholar
• CiprianiCIraniDBilezikianJPSafety of osteoanabolic therapy: a decade of experienceJ Bone Miner Res201227122419242823165426
   PubMed Web of Science ®Google Scholar
• CummingsSRSan MartinJMcClungMRFREEDOM TrialDenosumab for prevention of fractures in postmenopausal women with osteoporosisN Engl J Med2009361875676519671655
   PubMed Web of Science ®Google Scholar
• PapapoulosSChapurlatRLibanatiCFive years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extensionJ Bone Miner Res201227369470122113951
   PubMed Web of Science ®Google Scholar
• BoneHGChapurlatRBrandiMLThe effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extensionJ Clin Endocrinol Metab201398114483449223979955
   PubMed Web of Science ®Google Scholar
• SmithMREgerdieBHernàndezToriz NDenosumab HALT Prostate Cancer Study GroupDenosumab in men receiving androgen-deprivation therapy for prostate cancerN Engl J Med2009361874575519671656
   PubMed Web of Science ®Google Scholar
• OrwollETeglbjærgCSLangdahlBLA randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral densityJ Clin Endocrinol Metab20129793161316922723310
   PubMed Web of Science ®Google Scholar
• ChavassieuxPMeunierPJRouxJPPortero-MuzyNPierreMChapurlatRBone histomorphometry of transiliac paired bone biopsies after 6 or 12 months of treatment with oral strontium ranelate in 387 osteoporotic women: randomized comparison to alendronateJ Bone Miner Res201429361862823959630
   PubMed Web of Science ®Google Scholar
• BlakeGMFogelmanIBone: strontium ranelate does not have an anabolic effect on boneNat Rev Endocrinol201391269669724146028
   PubMed Web of Science ®Google Scholar
• FogelmanIBlakeGMStrontium ranelate for the treatment of osteoporosisBMJ200533075051400140115961793
   PubMed Web of Science ®Google Scholar
• KaufmanJMAudranMBianchiGEfficacy and safety of strontium ranelate in the treatment of osteoporosis in menJ Clin Endocrinol Metab201398259260123341486
   PubMed Web of Science ®Google Scholar
• ReginsterJYSeemanEDe VernejoulMCStrontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) studyJ Clin Endocrinol Metab20059052816282215728210
   PubMed Web of Science ®Google Scholar
• MeunierPJRouxCSeemanEThe effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosisN Engl J Med2004350545946814749454
   PubMed Web of Science ®Google Scholar
• BlakeGMFogelmanIThe correction of BMD measurements for bone strontium contentJ Clin Densitom200710325926517543560
   PubMed Web of Science ®Google Scholar
• Protelos and Osseor [webpage on the Internet]LondonEuropean Medicines Agency Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Protelos_and_Osseor/human_referral_prac_000025.jsp&mid=WC0b01ac05805c516fAccessed June 8, 2014
   Google Scholar
• CooperCFoxKMBorerJSIschaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case-control study in the CPRDOsteoporos Int201425273774524322476
   PubMed Web of Science ®Google Scholar
• SvanströmHPasternakBHviidAUse of strontium ranelate and risk of acute coronary syndrome: cohort studyAnn Rheum Dis20147361037104324651624
   PubMed Web of Science ®Google Scholar
• KanisJABianchiGBilezikianJPTowards a diagnostic and therapeutic consensus in male osteoporosisOsteoporos Int201122112789279821509585
   PubMed Web of Science ®Google Scholar
• GiustiABianchiGMale osteoporosisReumatismo201466213614325069495
   PubMedGoogle Scholar